LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・Pulse Biosciences Inc

Pulse Biosciences Inc

Затворен

СекторЗдравеопазване

14.28 4.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.15

Максимум

14.32

Ключови измерители
By Trading Economics
Приходи	-217K -19M
Продажби	86K 86K
EPS	-0.29
Марж на печалбата	-22,540.698
Служители	75
EBITDA	-228K -19M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+54.49% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-179M 958M
Предишно отваряне	9.89
Предишно затваряне	14.28

Настроения в новините

By Acuity

15%

85%

10 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.59 / 17.17 Подкрепа & съпротива

Pulse Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12.12.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12.12.2025 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12.12.2025 г., 17:32 ч. UTC

Придобивния, сливания и поглъщания

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12.12.2025 г., 17:31 ч. UTC

Придобивния, сливания и поглъщания

Orange to Buy the Stake for EU4.25B in Cash

12.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Argentina Predicts Record Wheat Crop -- Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

12.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 17:18 ч. UTC

Пазарно говорене

Печалби

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.12.2025 г., 16:47 ч. UTC

Пазарно говорене

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12.12.2025 г., 16:39 ч. UTC

Пазарно говорене

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pulse Biosciences Inc Прогноза

Ценова цел

By TipRanks

54.49% нагоре

12-месечна прогноза

Среден 22 USD 54.49%

Висок 22 USD

Нисък 22 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Pulse Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Pulse Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.59 / 17.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

10 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.